Shares of Agilent Technologies Inc (NYSE:A) ended Friday session in red amid volatile trading. The shares closed down -2.14 points or -4.55% at $44.88 with 2,507,018 shares getting traded. Post opening the session at $46.51, the shares hit an intraday low of $44.87 and an intraday high of $46.53 and the price vacillated in this range throughout the day. The company has a market cap of $13.90 billion and the numbers of outstanding shares have been calculated to be 324.38 million shares.
Agilent Technologies Inc (A) on August 30, 2016 introduced a new addition to its industry-leading line of gas chromatographs. The Agilent Intuvo 9000 GC solution offers users new innovative technology that will help laboratories meet operational, scientific and financial goals.
Designed together with customers, for customers, the Intuvo 9000 makes complex technology easy to use. Click-and-run connections eliminate ferrules, guard-chip technology extends column life, and the trim-free column eliminates retention time shifts due to column trimming maintenance.
With Intuvo Flow Technology chips and Smart ID Keys, the Intuvo 9000 system self-identifies installed components and self-configures methods. Operations like mid-column backflush are made routine by eliminating complex setup and extra calculators.
The touchscreen user interface provides quick access to system status and real-time data, and it guides the user through routine maintenance operations. Connection via smartphone or tablet notifies laboratory managers remotely of system status.
The new system, especially when coupled with mass spectrometry, is ideal for high-throughput contract laboratories, and for labs dealing with challenging sample matrices in fields such as food, environmental, chemical, pharma and forensics testing.
“We began this innovation journey by listening carefully to our customers around the world,” said Shanya Kane, Agilent vice president and general manager of the company’s Gas Chromatography Division. “The Agilent Intuvo 9000 GC system is so intelligent it will make lab technicians feel like GC experts. Lab managers will appreciate the boost in productivity, and business owners will enjoy improved financial outcomes.”
“Agilent has been the market leader in GC for the past 50 years,” said Mike McMullen, Agilent president and CEO. “With this heritage, coupled with an extensive network of industry partnerships and market experts, Agilent was uniquely positioned to take another leap forward by putting this transformational technology in the hands of our customers.”
Shares of Array Biopharma Inc (NASDAQ:ARRY) ended Friday session in red amid volatile trading. The shares closed down -0.25 points or -6.81% at $3.42 with 2.49 million shares getting traded. Post opening the session at $3.64, the shares hit an intraday low of $3.42 and an intraday high of $3.67 and the price vacillated in this range throughout the day. The company has a market cap of $462.19 million and the numbers of outstanding shares have been calculated to be 145.02 million shares.
Array Biopharma Inc (ARRY) on Sept. 1, 2016 announced that the FDA has accepted its New Drug Application (NDA) for binimetinib with a target action date under the Prescription Drug User Fee Act (PDUFA) of June 30, 2017. Array completed its NDA submission of binimetinib in late June 2016 based on findings from the pivotal Phase 3 NEMO (NRAS MELANOMA AND MEK INHIBITOR) trial in patients with NRAS-mutant melanoma. The FDA also indicated that it plans to hold an advisory committee meeting (ODAC) as part of the review process. As previously reported, Array is currently preparing for an Application Orientation Meeting (AOM) with the FDA in September 2016, which it expects will include a discussion of the NDA package including clinical risk / benefit.
“There are very few treatment advances beyond immunotherapy for this devastating disease, which impacts one out of five advanced melanoma patients,” said Victor Sandor, M.D., Chief Medical Officer, Array BioPharma. “Binimetinib is the first and only MEK inhibitor to demonstrate improvement on progression free survival in a Phase 3 trial for NRAS mutant melanoma patients.”